益心舒制剂联合常规治疗方案治疗冠心病心绞痛效果的Meta分析  

Meta-analysis of Therapeutic Efficacy of Yixinshu Preparation Combined with Conventional Therapy in the Treatment of Angina Pectoris of Coronary Heart Disease

作　　者：黄英杰 黄磊[1] 陶宇瑄 李海怡 张悦瑶 温俊茂 吴伟[2] HUANG Yingjie;HUANG Lei;TAO Yuxuan;LI Haiyi;ZHANG Yueyao;WEN Junmao;WU Wei(The First Clinical Medicine School,Guangzhou University of TCM,Guangzhou 510405,China;Dept.of Cardiovascular Medicine,the First Affiliated Hospital of Guangzhou University of TCM,Guangzhou 510405,China)

机构地区：[1]广州中医药大学第一临床医学院,广州510405 [2]广州中医药大学第一附属医院心血管内科,广州510405

出　　处：《中国药房》2021年第3期339-345,共7页China Pharmacy

基　　金：国家自然科学基金资助项目(No.81673923);广州中医药大学第一临床医学院“创新强院”团队孵化计划(No.2018XXDT01)。

摘　　要：目的:系统评价益心舒制剂联合常规治疗方案对比常规治疗方案治疗冠心病心绞痛的效果,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、中国生物医学文献数据库、中国知网、万方数据库和维普网,检索时限为2012年1月1日-2020年10月1日,收集益心舒制剂联合常规治疗方案(试验组)对比常规治疗方案(对照组)治疗冠心病心绞痛的随机对照试验(RCT)。对符合标准的文献进行资料提取后,采用Cochrane系统评价员手册5.3评价纳入研究的质量,采用Stata 15.0软件进行Meta分析。结果:共纳入23项RCT,合计2853例患者。Meta分析结果显示,试验组患者在心绞痛疗效[RR=0.92,95%CI(0.87,0.97),P<0.05]、心绞痛发作次数[SMD=-0.98,95%CI(-1.09,-0.87),P<0.05]、心绞痛发作持续时间[SMD=-0.77,95%CI(-0.88,-0.67),P<0.05]、心电图疗效[RR=0.91,95%CI(0.84,0.98),P<0.05]、中医证候改善率[RR=0.89,95%CI(0.85,0.94),P<0.05]方面均优于对照组,差异均有统计学意义。结论:益心舒制剂联合常规治疗方案治疗冠心病心绞痛在提高患者心绞痛疗效、心电图疗效,改善中医证候,降低心绞痛发作次数、心绞痛发作持续时间方面较常规治疗方案更优。OBJECTIVE:To systematically evaluate therapeutic efficacy of Yixinshu preparation combined with conventional treatment plan for angina pectoris of coronary heart disease(CHD)vs.conventional treatment plan,and to provide evidence-based reference for clinical drug use.METHODS:Retrieved from Cochrane library,PubMed,Embase,CBM,CNKI,Wanfang database and VIP,randomized controlled trials(RCTs)about Yixinshu preparation combined with conventional treatment plan(trial group)versus conventional treatment plan(control group)for angina pectoris of coronary heart disease were collected during Jan.1st in 2012 to Oct.1st in 2020.After extracting the data,the quality of included studies were evaluated with Cochrane System Evaluator Handbook 5.3;Meta-analysis was performed by using Stata 15.0 software.RESULTS:A total of 23 RCTs involving 2853 subjects were included.The results of Meta-analysis showed that the efficacy of angina pectoris[RR=0.92,95%CI(0.87,0.97),P<0.05],the times of angina pectoris attack[SMD=-0.98,95%CI(-1.09,-0.87),P<0.05],the duration of angina pectoris[SMD=-0.77,95%CI(-0.88,-0.67),P<0.05],ECG curative effect[RR=0.91,95%CI(0.84,0.98),P<0.05]and the improve rate of TCM syndromes[RR=0.89,95%CI(0.85,0.94),P<0.05]in trial group were all better than control group,with statistical significance.CONCLUSIONS:Yixinshu preparation combined with conventional treatment plan is better than conventional treatment plan in terms of improving therapeutic efficacy of angina pectoris and ECG,TCM syndrome improvement rate,as well as reducing the frequency of angina pectoris attack,angina pectoris attack duration.

关 键 词：益心舒 联合用药 冠心病 心绞痛 效果 META分析 

分 类 号：R972[医药卫生—药品]